Dr. Reddy’s Q1 Review – Weak Quarter, Higher Costs Impacted Profitability: ICICI Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dr. Reddy’s Laboratories Ltd.’s reported Q1 FY22 performance below our estimates due to higher expenses.

Revenue grew 11.4% y-o-y to Rs 49.2 billion (our estimate: Rs 50.2 billion) driven by India, Europe and rest of world markets.

Ebitda margin at 18.3% was lower 300 basis points q-o-q due to lower gross margin and higher selling, general and administrative expenses.

U.S. sales dropped 1.7% q-o-q to $235 million due to price erosion and we expect it to improve in coming quarters led by new launches including generic Vascepa.

We expect the growth momentum in branded generics business (India and emerging markets), supplies of Sputnik V vaccine and new launches in U.S. to continue in coming quarters supporting Dr. Reddy’s overall growth.

Click on the attachment to read the full report:

ICICI Securities Dr. Reddys Q1FY22 Results Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
editorpen Governmental News Finance News

Source link

Back to top button